Joseph Bertelsen appointed CCO of Nuclera

Nuclera has announced that it has appointed Joseph Bertelsen as chief commercial officer (CCO).
Joseph has over 20 years of experience in commercial leadership within the life sciences and drug development industries, and brings with him an extensive sales record that will be instrumental to the commercial launch strategy and explosive adoption of Nuclera’s eProtein Discovery platform’, according to the company’s press release.
Previously, Joseph worked at the Institute for Protein Innovation, where he was the director of commercialisation. He has also held various senior positions at protein-focused companies, such as Diagenode and Abcam.
Commenting on his new role, Joseph Bertelsen said: “Nuclera is disrupting the protein market with their technology allowing researchers to more easily and quickly have access to proteins for their research. Their benchtop technology has the potential to greatly reduce costs and timelines associated with the drug discovery process. I’m excited to be joining the team at such an exciting phase of the journey to drive adoption of Nuclera’s eProtein Discovery.”
Dr Michael Chen, CEO and co-founder of Nuclera, added: “Appointing our first chief commercial officer marks an exciting step in Nuclera’s journey. With Joe’s strong track record and experience in achieving revenue growth, I look forward to partnering with him on rapidly increasing the number of protein makers that use our eProtein Discovery system to make proteins accessible.”